(a) Rluc2-Met and mAmetrine-Met spontaneous multimerization and dissociation with methyl farnesoate addition. The treatment denoted as “mAme” consisted of cells expressing Rluc2-Met and free mAmetrine. This treatment provides the BRET ratio that is Met multimerization independent (e.g., baseline BRET ratio). (b) Methyl farnesoate-stimulated dimerization of Rluc2-SRC and mAmetrine-Met. (c) Luciferase reporter gene activation in cells expressing Met and SRC-Gal4 with increasing concentrations of methyl farnesoate. All data are presented as mean and standard deviation (n = 3). An asterisk denotes a significant difference from the 0 μM methyl farnesoate treatment (ANOVA).